Functional Outcome Measures in Children with Osteogenesis Imperfecta - Osteogenesis Imperfecta - page 443

[37] van Brussel M, van der Net J, Hulzebos E, Helders PJ,

Takken T. The Utrecht approach to exercise in chronic child-
hood conditions: the decade in review. Pediatr Phys Ther
2011;23(1):2-14.

with osteogenesis imperfecta. J Pediatr Endocrinol Metab
2005;18(1):43-53.

[42] Castillo H, Samson-Fang L. American academy for cerebral

palsy and developmental medicine treatment outcomes com-
mittee review panel. Effects of bisphosphonates in children with
osteogenesis imperfecta: an AACPDM systematic review. Dev
Med Child Neurol 2009;51(1):17-29.

[38] Ward KA, Adams JE, Freemont TJ, Mughal MZ. Can bisphos-

phonate treatment be stopped in a growing child with skeletal
fragility? Osteoporos Int 2007;18(8):1137-40.

[39] Forin V, Arabi A, Guigonis V, Filipe G, Bensman A, Roux C.

Beneits of Pamidronate in children with osteogenesis imper-
fecta: an open prospective study. Joint Bone Spine 2005;
72(4):313-8.

[43] Engelbert RHH, Scheper MC. Joint hypermobility with and

without musculoskeletal complaints: a physiotherapeutic
approach. Int Musculoskel Med 2011;33(4):146-51.

[44] Shapiro JR, Germain-Lee EL. Osteogenesis imperfecta: effect-

ing the transition from adolescent to adult medical care.
J Musculoskelet Neuronal Interact 2012;12(1):24-7.

[40] Blair SN, Cheng Y, Holder JS. Is physical activity or physical it-

ness more important in deining health beneits? Med Sci Sports
Exerc 2001;33(6 Suppl):S379-99. [45] Myers J, Prakash M, Froelicher VF, Do D, Partington S, Atwood

JE. Exercise capacity and mortality among men referred for
exercise testing. N Eng J Med 2002;346:793-801.

[41] Dimeglio LA, Ford L, McClintock C, Peacock M. A comparison

of oral and intravenous bisphosphonate therapy for children